10x Genomics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Outlook for 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
10x Genomics (TXG) Misses Q4 EPS by $3.64, Revenues Beat; Offers FY21 Revenue Mid-Point Guidance Below Consensus
February 17, 2021 5:05 PM EST10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($3.87), $3.64 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $112.2 million versus the consensus estimate of $100.4 million.
Recent Highlights
Revenue was $298.8 million for the full year and $112.2 million for the fourth quarter of 2020,... More